XOMA Royalty Corporation

XOMA

US98419J2069

Entertainment Production

Market Closed - Nasdaq Other stock markets 02:30:00 24/01/2026 am IST			5-day change	1st Jan Change
26.70 ^USD	-0.82%		+1.25%	+0.41%

16/01	XOMA Royalty Corporation Announces Departure of Thomas Burns as Senior Vice President, Finance, Effective January 12, 2026	CI
12/01	XOMA Royalty Appoints New CFO; Shares Fall	MT

Xoma Royalty Completes Acquisition of Lava Therapeutics

Published on 11/21/2025 at 08:29 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about XOMA Royalty Corporation

16/01	XOMA Royalty Corporation Announces Departure of Thomas Burns as Senior Vice President, Finance, Effective January 12, 2026	CI
12/01	XOMA Royalty Appoints New CFO; Shares Fall	MT
12/01	Xoma Royalty announces CFO transition	RE
12/01	XOMA Royalty Corporation Announces CFO Changes, Effective January 12, 2026	CI
30/12	Xoma Royalty and Takeda execute strategic royalty sharing transaction and amend existing agreement for mezagitamab	RE
30/12	XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio	MT
30/12	XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction	CI
16/12	Xoma Royalty enters into agreement to acquire Generation Bio	RE
15/12	XOMA Royalty Corporation entered into an agreement to acquire Generation Bio Co. for $28.92 million.	CI
05/12	XOMA Royalty Completes Acquisition of Mural Oncology	MT
05/12	Xoma Royalty announces closing of transaction to acquire Mural Oncology plc	RE
04/12	XOMA Royalty Corporation completed the acquisition of Mural Oncology plc from group of shareholders.	CI
26/11	Mural Oncology Reports Final Consideration Payable on Closing of Acquisition by Xoma	MT
21/11	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
21/11	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE
20/11	XOMA Royalty Corporation completed the acquisition of LAVA Therapeutics N.V..	CI
14/11	Xenotherapeutics Inc signed a definitive arrangement agreement to acquire Repare Therapeutics Inc. for $78.7 million.	CI
12/11	XOMA Royalty Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	CI
12/11	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
25/25/25	Mural Oncology Shareholders Approve $36.2 Million Sale to XOMA Royalty Unit	MT
17/25/17	XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline	MT
17/25/17	Xoma Royalty and Lava Therapeutics announce amendment to purchase agreement	RE
04/25/04	Xoma Royalty says may offer and sell shares of common stock of up to $75 million - SEC filing	RE
03/25/03	XOMA Royalty Extends Tender Offer to Acquire Lava Therapeutics	MT

Chart XOMA Royalty Corporation

Duration

Period

XOMA: Dynamic Chart

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Employees

Sector

Entertainment Production

Calendar

05/03 - Q4 2025 Earnings Release (Projected)

More about the company